TrialNeurology2017

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Eva Havrdova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.